These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 12181402)

  • 21. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
    Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
    Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
    Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
    J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
    Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
    Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
    Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.
    Tipirneni E; Buttar A; Brettler D; Miron P; Bathini V
    Ann Hematol; 2012 Apr; 91(4):637-8. PubMed ID: 21833478
    [No Abstract]   [Full Text] [Related]  

  • 28. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
    Van Limbergen H; Beverloo HB; van Drunen E; Janssens A; Hählen K; Poppe B; Van Roy N; Marynen P; De Paepe A; Slater R; Speleman F
    Genes Chromosomes Cancer; 2001 Mar; 30(3):274-82. PubMed ID: 11170285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
    Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
    Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
    Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
    Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene.
    Murga Penas EM; Cools J; Algenstaedt P; Hinz K; Seeger D; Schafhausen P; Schilling G; Marynen P; Hossfeld DK; Dierlamm J
    Genes Chromosomes Cancer; 2003 May; 37(1):79-83. PubMed ID: 12661008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
    Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
    Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
    Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 39. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.